Monthly Contraceptive Pill Shows Promise in Pig Study

A device that releases synthetic hormones slowly over time could one day provide a more practical alternative to daily birth control pills, say scientists.


Researchers at MIT have developed an oral contraceptive pill that releases hormones slowly into the stomach with the goal of developing a product that only needs to be taken on a once-a-month basis. A trial of the device in pigs, described yesterday (December 4) in Science Translational Medicine, indicates that the technology is as good as the daily birth control pill at maintaining high levels of contraceptive hormones in the blood.

“The concept of a monthly oral contraceptive pill is attractive and has the potential to broaden contraceptive choice,” Diana Mansour, vice president of the Faculty of Sexual and Reproductive Healthcare in the UK, tells the BBC. “However, the development of such a novel contraceptive is still in its early stages. We look forward to further research in this area.”

While the oral contraceptive pill is up to 99 percent effective for women who take one a day, that efficacy drops with every missed dose, meaning that in reality, about nine women in every 100 become pregnant while on the pill.

The technology described in the current study consists of a star-shaped device, packed into a capsule for easy swallowing. Once it reaches the stomach, the capsule dissolves and the device unfolds, becoming too large to exit the stomach easily but not large enough to create an obstruction.

There, it begins gradually releasing levonorgestrel, a synthetic progestogen, and continues to do so over the next few weeks. After having released its contents, it breaks down and can pass safely through the digestive system.

When they tested the device in six female pigs, the researchers found that levonorgestrel levels remained high in the blood even 21 days after administration of the pill, and was still detectable after 29 days. By contrast, five pigs given a single oral dose of levonorgestrel showed just trace amounts of the hormone in their blood two days later.

Lyndra Therapeutics, a spinoff company that several of the study’s coauthors are involved in, is now working on developing the technology to tailor dosages to humans and make sure the hormones are released at the right rate, The Guardian reports.

The same team has already used the technology to deliver other types of drugs, and study coauthor Robert Langer tells The Guardian that he envisages slow-release pills being applicable to many diseases in the future. “I hope there will be pills that people could swallow that could last for any length of time to treat different diseases, like mental health diseases and opioid addiction, Alzheimer’s, [AIDS].”

Catherine Offord is an associate editor at The Scientist. Email her at

July/August 2020

Life During a Pandemic

Understanding the virus is just the beginning


Sponsored Product Updates

Horizon Discovery introduces single cell RNAseq-linked CRISPR screening service
CRISPR-based screening technology platform to address critical gaps in target ID and validationSingle cell RNAseq-linked pooled CRISPR screening offers high-quality screening data and biological insight
Coronavirus SeroAssay
Multiplexed coronavirus serological testing for examining vaccine efficacy
UV Disinfection in the Age of SARS-CoV-2
Download this white paper to learn about choosing the best wavelength for optimal disinfection and decontamination!
A Multi-omics Approach to Overcome Solid Tumor Drug Resistance
Download this research summary to learn about how single-cell proteomics and metabolomics methods unlock drug resistance mechanisms!